Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
Street Ideas Just Put Enlivex (Nasdaq: ENLV) At The Top Of The Watchlist This Morning—Wednesday, August 12, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Look At ENLV While It’s Still Early… August 12, 2026 Dear Reader, The morning update is here. Enlivex Ltd. (Nasdaq: ENLV) topped the watchlist last night — and with the bell under 90 minutes out, it is still the name to have on the radar. The FDA RMAT designation for Allocetra is still in place. The $400M institutional commitment at $5 and $6 per share is still pending — with an option for that same institution to deploy another $400M over the next 36 months. The RAIN token treasury stood near $1.1Bn as of July 18. Rain protocol platform activity hit $860M in July — up 622% over June. And fewer than 4M shares are listed as available to the public. None of that changed overnight. What does change when the bell rings is the window to get familiar with this name before the market gets moving. According to Benzinga, H.C. Wainwright's Raghuram Selvaraju raised his published Bullish target to $80 last week — against a name that has been trending near $2. A 182-patient Phase IIb trial is active across three countries. The FDA has requested a Type B meeting following the RMAT designation. With under 90 minutes to the bell, there is still time. Take a close look at ENLV before the open.
Before going further, there are a few numbers worth taking a look at. Right now, fewer than 4M shares are currently listed as available to the public. That is a small float by any measure on Nasdaq. Small floats matter because they can amplify price movement when attention shifts toward a name. ENLV has been near the $2 range recently. Last week, H.C. Wainwright analyst Raghuram Selvaraju raised his published Bullish target to $80, according to Benzinga. That gap between where ENLV is currently trending and where his target sits is worth factoring in. Then there is the balance sheet. Enlivex posted FY2025 net income of $1.23Bn and diluted EPS of $25.48. Total treasury and derivative assets came in at $2.31Bn. Shareholders' equity reached $1.93Bn. Those figures were driven primarily by appreciation in RAIN token holdings — and that distinction matters when sizing up what is behind them. Two Engines Running at Once — Here Is What ENLV Actually Does
Two things are running at Enlivex simultaneously and both are material to understanding the name. The first is a clinical program. Allocetra is an off-the-shelf, allogeneic cell therapy built to reprogram macrophages back into their homeostatic state — resolving chronic inflammation at the source rather than suppressing it broadly. The primary target is age-related primary knee osteoarthritis. The 182-patient Phase IIb trial spans the United States, Denmark, and Poland, targeting patients aged 64 and older. Top-line data is expected in 2027. Following the RMAT designation, the FDA requested a Type B meeting to align on Phase IIb design — a structured regulatory dialogue that carries real weight at this stage. The second is a digital asset treasury built around the RAIN protocol on Arbitrum. As of July 18, 2026, Enlivex held approximately 79.55Bn RAIN tokens valued near $1.1Bn, with an unaudited mark-to-market NAV per share of $66.16. The company also holds an option on 271.37Bn additional tokens at $0.0033 per token — with the option's intrinsic value estimated near $2.23Bn as of May 2026. Both sides of this company are active. Both are worth understanding before forming any view. What Is Actually Driving the Story Behind (ENLV) Right Now
There are two separate storylines worth understanding here. One is clinical and regulatory. The other is financial. Both are relevant to how this name gets evaluated. On the clinical side, start with what RMAT designation actually requires. The FDA established this pathway for regenerative therapies targeting serious conditions where there is a genuine unmet need and preliminary clinical evidence supporting the therapy's potential. The agency reviews the data and decides whether the program clears that bar. Less than half of all applications do. Allocetra cleared it. The basis was Phase IIa data demonstrating statistically significant and durable improvements in pain and physical function in patients 60 and older — results that held at both the three-month and six-month marks. The FDA reviewed those results and responded with RMAT designation and a request for a Type B meeting. That sequence matters. Now consider what the designation is pointing toward. The CDC estimates arthritis will affect approximately 78M Americans by 2040. The therapeutics market built around osteoarthritis currently stands at $10.84Bn globally, with projections putting it near $26.31Bn by 2035 at a 9.27% annual growth rate. 
Within that market, the 64-plus primary OA group — the exact population Allocetra targets in Phase IIb — has no approved therapy that modifies the underlying disease. Every approved option today manages pain. None of them change the course of the condition. Allocetra's approach works through macrophage polarization — restoring the immune system's natural resolution capacity rather than suppressing it. That is a structurally different mechanism in a space that currently has no approved disease-modifying answer. On the financial side, the RAIN protocol numbers from July are worth noting. Platform activity reached $860M for the month — a 622% increase over June. The Rain Foundation's long-range throughput targets sit at $1.3Bn in 2027, $12Bn in 2028, and $33Bn in 2029. At those levels, the buyback-and-burn mechanism tied to the protocol would generate net fees of $24M, $216M, and $600M in those respective years. That mechanism is a structural demand driver for the RAIN token — the same token that makes up the bulk of the treasury ENLV carries on its balance sheet. The gap between the reported NAV per share and where ENLV has been recently priced is substantial. The readers best positioned to evaluate that gap are the ones who take the time to understand both sides of what is driving it. July 13, 2026
FDA RMAT Designation for Allocetra
The FDA granted Regenerative Medicine Advanced Therapy designation to Allocetra for age-related symptomatic knee osteoarthritis in patients 64 and older, opening pathways to accelerated approval eligibility and intensive early FDA engagement. Following the grant, the FDA requested a Type B meeting to discuss the Allocetra development program and Phase IIb planning. See full story here. July 28, 2026
$400M Institutional Commitment
A single institution agreed to purchase $400M of ENLV ordinary shares at $5 or $6 per share — premiums of 17.4% and 40.8% to the July 27 close — with an optional right to deploy an additional $400M on the same terms over the next 36 months. Closing remains subject to shareholder approval. See full story here. July 30, 2026
RAIN Protocol Activity Reaches $860M
The Rain protocol recorded $860M in platform activity for July 2026 — a 622% increase over June — with long-range throughput targets of $1.3Bn (2027), $12Bn (2028), and $33Bn (2029). See full story here. July 20, 2026
Treasury NAV Per Share of Around $66
As of July 18, 2026, Enlivex held approximately 79.55Bn RAIN tokens valued near $1Bn, with an unaudited mark-to-market NAV per ordinary share of around $66. See full story here. June 2026
EULAR 2026 Oral Presentation
Allocetra's Phase IIa data was selected for an oral podium presentation at the EULAR European Congress of Rheumatology in London, where Prof. Philip Conaghan presented statistically significant and durable improvements in pain and function in patients 60 and older at three and six months. See full story here. May 2026
Phase IIb First U.S. Patient Dosed
Enlivex dosed the first patient at a U.S. site in its 182-patient Phase IIb Allocetra trial, targeting patients 64 and older across the United States, Denmark, and Poland following FDA IND and Danish Medicines Agency clearances. See full story here. March 25, 2026
FY2025 Full-Year Results
Enlivex reported FY2025 net income of $1.23Bn and diluted EPS of $25.48, with total treasury and derivative assets of $2.31Bn and shareholders' equity of $1.93Bn as of December 31, 2025. See full story here. Here Are 5 Reasons Why (ENLV) Is At The Top Of Our Watchlist
This Morning — Wednesday, August 12, 2026… 1. FDA Designation: after Allocetra received RMAT status on July 13, ENLV gained access to intensive FDA engagement and potential accelerated approval eligibility. 2. RAIN Treasury: holding approximately 79.55B RAIN tokens valued near $1.1B as of July 18, ENLV also reported an unaudited mark-to-market NAV of $66.16 per share. 3. Phase IIb: with a 182-patient study underway across the U.S., Denmark, and Poland, ENLV is advancing Allocetra toward top-line data expected in 2027. 4. Big Commitment: with one institution agreeing to purchase $400M of ordinary shares at $5 and $6, ENLV has attracted a sizable financial commitment subject to shareholder approval. 5. Small Float: with fewer than 4M shares listed as available to the public, ENLV’s small float could witness the potential for significant swings if demand starts to shift. Take A Look At ENLV While It’s Still Early…
ENLV is not a one-headline name right now. It is a name with several distinct developments running at the same time — and that is precisely what makes it worth understanding this morning. Fewer than 4M shares are listed as available to the public. The FDA has designated Allocetra as an RMAT therapy for age-related knee osteoarthritis in patients 64 and older. A single institution has committed to a $400M placement at $5 to $6 per share, pending shareholder approval. A 182-patient Phase IIb trial is underway across three countries with data expected in 2027. Set the clinical and regulatory picture aside for a moment and look at the treasury. As of July 18, Enlivex held RAIN tokens valued near $1.1Bn, with a reported unaudited NAV per share of $66.16. Rain protocol platform activity reached $860M in July — a 622% increase over June. And according to Benzinga, H.C. Wainwright's Raghuram Selvaraju raised his published Bullish target to $80 last week, while ENLV has been hovering near $2. Each of those data points is worth studying on its own. Together, they form a picture that is harder to dismiss. Take a close look at ENLV while it’s still early. Street Ideas has all eyes on ENLV this morning. Talk soon. Paul Prescott
Co-Founder & Managing Editor, Street Ideas |
0 التعليقات:
إرسال تعليق